Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women.

[1]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[2]  J. Seddon,et al.  Age-related eye diseases: impact of hormone replacement therapy, and reproductive and other risk factors. , 2000, International journal of fertility and women's medicine.

[3]  R. Klein,et al.  Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the beaver dam eye study. , 2000, American journal of ophthalmology.

[4]  J. Seddon,et al.  Do age-related macular degeneration and cardiovascular disease share common antecedents? , 1999, Ophthalmic epidemiology.

[5]  J. Mant,et al.  Oral contraception and eye disease: findings in two large cohort studies , 1998, The British journal of ophthalmology.

[6]  R. Klein,et al.  Incidence of age-related cataract: the Beaver Dam Eye Study. , 1998, Archives of ophthalmology.

[7]  M. Subbiah.  Mechanisms of Cardioprotection by Estrogens , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[8]  M. C. Leske,et al.  Lens opacities, demographic factors and nutritional supplements in the Barbados Eye Study. , 1997, International journal of epidemiology.

[9]  J. J. Wang,et al.  Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. , 1997, Australian and New Zealand journal of ophthalmology.

[10]  J. Manson,et al.  Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. , 1997, Circulation.

[11]  J. Manson,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[12]  J. Alsina.  Benefits of hormone replacement therapy--overview and update. , 1997 .

[13]  J. Manson,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[14]  T. Sellers,et al.  Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. , 1995, American journal of public health.

[15]  I. Dielemans,et al.  Macular degeneration and early menopause: a case-control study , 1995, BMJ.

[16]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[17]  H. Luukinen,et al.  Prevalence and risk factors of lens opacities in the elderly in Finland. A population-based study. , 1995, Ophthalmology.

[18]  R. Klein,et al.  Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. , 1994, Transactions of the American Ophthalmological Society.

[19]  Z. Gregor,et al.  Oestrogens and macular holes: A postal questionnaire , 1994, Eye.

[20]  M. Klag,et al.  Plasma lipoprotein levels as predictors of cardiovascular death in women. , 1993, Archives of internal medicine.

[21]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[22]  R. Klein,et al.  Cataracts and macular degeneration in older Americans. , 1982, Archives of ophthalmology.

[23]  Maltzman Ba,et al.  Senile macular degeneration and risk factors: a case-control study. , 1979, Annals of ophthalmology.

[24]  M. Varga.  Recent experiences on the ophthalmologic complications of oral contraceptives. , 1976, Annals of ophthalmology.

[25]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .